Mechanical circulatory support devices Flashcards

1
Q

Hypoxia after LVAD implantation

A

Optimize ventilator settings –> if refractory, consider intracardiac shunt (PFO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Management of aortic valvulopathy after LVAD implantation

A

a. If recovery of the LV is not anticipated, i.e., destination therapy, consider suturing AV leaflets close if AI
b. If recovery is likely, then aortic replacement with a tissue valve is probably the best solution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Management of mitral valvulopathy after LVAD implantation

A
  • Mitral valve regurgitation is effectively treated by implanting an LVAD.
  • Mitral stenosis needs replacement with bioprosthetic valve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Management of tricuspid valvulopathy after LVAD implantation

A

If preop Tricuspid regurg is severe, limited data suggest improved outcomes after LVAD with concomitant TV repair or replacement with bioprosthetic valve.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

LVAD pump thrombosis symptoms

A

Profound heart failure; hematuria, pump alarms, power spikes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

LVAD pump thrombosis diagnostic test

A

TTE; LDH; D-dimer; RHC; CT angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

LVAD pump thrombosis treatments

A

Inotropes, diuresis, o2, Intraventricular thrombolysis, pump exchange.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the incidence of requirement for temporary MCS after cardiac surgery?

A

0.2-0.6%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Who invented the IABP and in which year?

A

Adrian Kantrowitz 1967

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the major effect of IABP? What are the minor/secondary effects?

A

Decreased afterload (15%) and increased coronary perfusion (21% increase in flow to ischemic areas)

Decreased LV wall tension, decreased O2 consumption, reduced LVEDV, LVESV, reduced preload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the IABP timed to activate towards?

A

ECG R wave and arterial pressure tracing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the 3 major indications for IABP?

Bonus: name 5 more indications for IABP

A

Cardiogenic shock, post-pericardiotomy low cardiac output, uncontrolled myocardial ischemic pain

Bonus: high risk/failed PCI, high grade left main, poorly controlled ventricular arrhythmias before or after operation, post-MI VSDs or post-MI acute MR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the landmark for puncture of the femoral artery? What are the access sites for IABP?

A

1-2 cm below the mid-inguinal point (mid point of the ASIS and pubic symphysis not to be confused with the mid point of the inguinal ligament which is the landmark for the femoral nerve) or 1-2cm above the inguinal fold (not always accurate)

Femoral (most common), abdominal aorta, iliac arteries, axillary arteries, direct insertion into ascending aorta (intra-op)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What size is the IABP?

A

7 Fr (1 Fr = 0.33mm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the complicate rate associated with IABP? What are the complications?

A

20%

Leg ischemia, balloon rupture, balloon thrombosis, pseudoaneurysm, lymphocele, lymphatic fistula, AV fistula, infection, septicemia, femoral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How can you tell if a balloon ruptures and what do you do if the balloon ruptures?

A

Blood will be seen in the balloon catheter and an alarm may go off
Deflate the balloon forcibly and remove the balloon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What do you do if pain, decreased sensation and compromised circulation occur in a IABP?

A

Promptly remove the balloon and if the patient is balloon dependent, place an IABP in the contralateral groin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the IABP SHOCK II trial and what did it show?

A

This trial randomized 600 patients with acute MI and cardiogenic shock who were planned to undergo revascularization to either IABP or medical therapy. There was no difference in the 30 day mortality and no difference in adverse advents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the average overall survival for patients put on temporary MCS?

A

21-41%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the criteria for cardiogenic shock?

A

Cardiac index < 2.2L/m2, sBP <90, mean PCWP or CVP >20mmHg and concomitant use of high doses of 2 or more inotropes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are three drugs commonly used in RV failure?

A

Milrinone, NO and vasopressin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the differences between CPB and ECLS?

A

ECLS is a continuous flow circuit, without areas for stasis like the venous reservoir or cardiotomy suction reservoir, which means lower doses of heparin are required and less activation of the inflammatory response and coagulopathy. ECLS provides partial cardiorespiratory support. ECLS has a diffusion membrane instead of a microporous membrane. There is no way to de-air in the ECMO circuit, there is no blood air interface.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the components of the ECMO circuit?

A

Venous cannula, Membrane oxygenator, Centrifugal pump, Heat exchanger, Arterial cannula

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the cannulation sites for central and peripheral ECMO?

A

Central: ascending aorta and right atrium
Peripheral: axillary, femoral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What size cannula are typically used?

A

Arterial 16-20Fr

Venous 18-25Fr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What must you be concerned about with axillary artery cannulation?

A

Progressive arm edema. Treatment is partial occlusion of distal axillary artery with vessel loop. Make sure you have a right radial artery arterial line to ensure you know the right arm is perfused when you cannulate the right axillary.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What does ECLS do to the heart in terms of preload/afterload to the right/left hearts? What can be done to fix this?

A

ECLS can unload the RV, but will not unload a compromised LV. It can reduce LV preload but will increase LV afterload slightly. A poorly contractile LV may not be able to eject and can remain dilated, which increases myocardial O2 consumption. A LV vent can be inserted to decompress a dilated LV.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the complications of ECMO?

A

Bleeding, renal failure requiring dialysis (47%), stroke (10%), bacteremia or mediastinitis (23%), leg ischemia (70%), oxygenator failure requiring change (43%) and pump change (13%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What do you do when you find clot in the pump head?

What do you do when there is leakage of plasma across the membrane?

A

Pump head change

Monitor, but this may cause increased resistance to flows and necessitate oxygenator change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

How do you do central VA ECMO

A

The eopa cannula is inserted into the ascending aorta. The cannula is the same size as the regular cannula 20Fr.

The venous cannula is a single stage Bard cannula, large diameter (38Fr) and it is inserted to sit in the middle of the RA. The purse string is made halfway between the RAA and the IVC. The Bard cannula does not sit too deeply. They must be secured with double plegeted (bovine pericardium) sutures. Use special VAD tourniquets. Tunnel the cannula through the skin, the aortic cannula through near the left costal margin, the venous cannula through the right costal margin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How do you vent the LV?

A

IAS via balloon atrial septostomy, or LV via RSPV or LV via apex or Impella.

Hook up your vent to 1/4 inch tubing then use a 1/4 to 3/8ths connector, Y that into a 3/8-3/8-3/8ths connector. The benefit of this approach is reduced risk of stasis of the vent drainage and you can put a flow probe on the tubing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is oxygenation dependent on?
What is sweep?
What is CO2 diffusion dependent on?

A

Blood flow
Gas flow
Gas flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What do you do in an LVAD with AI?

A

Park’s stitch to create aortic stenosis and reduce the AI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What are the ACT targets in VV ECMO and VA ECMO?

A

VV ECMO - ACT 150

VA ECMO - ACT 180

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the predictor of needing MCS post-cardiotomy?

A

low MVO2 <60%, oliguria, low cardiac output, multiple high dose inotropes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is the Cardiohelp ECLS device?

A

It is a compact ECLS device with a low priming volume and integrated oxygenator which allows transport of patients on ECLS in and out of hospital.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the TandemHeart? Where is it used and where do the cannulas sit? What are some alternative uses for the device? How much flow can it support?

A

It is a pVAD that is approved for up to 6 hours of continuous usage by the FDA. It is primarily used in high risk PCI. It can be inserted percutaneously or open, typically with the inflow cannula positioned transseptally into the LA and the outflow cannula positioned in the femoral artery. It can also be used as an RVAD with the inflow cannula in the femoral vein and the outflow cannula percutaneously placed into the main PA. If inserted percutaneously, it can be entirely removed in the ICU without opening the chest. It can provide up to 4L of flow.

It can be used off label with an oxygenator or for more than 6 hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is Centrimag? What can it support and what is it FDA approved for? How much flow can it support?

A

It is a centrifugal pump that can be used to provide both LVAD and RVAD support. It is FDA approved for RVAD support up to 30 days and LVAD support up to 6 hours. It is typically inserted via central cannulation via median sternotomy. It can be outfitted with an oxygenator and provides up to 10L of flow?

39
Q

How does the Impella work, what does it do for the heart physiologically?

A

It increases CO, reduces myocardial oxygen demand by unloading the LV, increases coronary perfusion

40
Q

What are the key ventilatory parameters during temporary MCS?

A

Peak inspiratory pressure < 35 cm H2O. O2 initially set at 100% and gradually decreased, partial pressure of O2 maintained between 85-100 mmHg, PEEP of 5 mmHg

41
Q

What are the anticoagulation/bleeding parameters?

A

Platelet counts decrease in the first 24 hrs of support, transfusion of platelets to maintain plts above 50k, or 100k if bleeding, FFP and cryo for fibrinogen over 250mg/dL. IV heparin starting at 8-10 ug/kg/h to maintain a pTT of 45-55.

42
Q

What are the fluid management parameters?

A

Aggressive diuresis to minimize 3rd spacing. If response to diuretic therapy is suboptimal, SLED or IHD is initiated.

43
Q

Would you put a mechanical or bioprosthetic aortic/mitral valve into a patient undergoing LVAD and why?

A

Bioprosthetic because if there is stasis with LVAD, there is a high risk for thrombosis of the mechanical valve

44
Q

Who performed the first LVAD and when?
Who performed the first successful LVAD?
Who performed the first successful bridge to transplant LVAD?

A

DeBakey in 1963, patient survived for 4 days
DeBakey in 1966, patient survived for 10 days and was weaned off
Texas Heart in 1978 using the Model 7 abdominal LVAD

45
Q

What was the first pump to be managed in an outpatient setting?

A

Heartmate XVE

46
Q

What was the first trial to demonstrate the success of LVADs?

A

Heartmate XVE in the REMATCH trial which showed a 50% absolute reduction in mortality at 1 and 2 years.

47
Q

What are the pros and cons of continuous flow LVADs versus pulsatile flow LVADs?

A

Continuous flow LVADs are mechanically simpler, more resistant to wear and tear and smaller than pulsatile flow LVADs. In the Heartmate II DT trial, were shown to need reduced replacement, reduced sepsis, respiratory failure, renal failure, arrhythmias and rehospitalization.

However, CF LVADs can cause increased GI bleeding and degeneration of smooth muscle and elastic fibers in aortic tissue as well as stasis and thrombus formation in the carotid bulb and aortic valve cusps.

Overall, CF technology remains the future of MCS.

48
Q

What are the types of VADs available currently?

A

Centrimag - surgical - centrifugal - temporary - flows up to 10L/min
Impella - percutaneous - left sided support - flows up to 5L/min - right sided version available
TandemHeart - percutaneous - left atrial -> left femoral via transseptal approach - flows up to 4/min
Heartmate II - surgical - FDA approved for BTT (2008) and DT (2010)
Jarvik 2000 - surgical - trial pending - FDA investigational device exemption
INCOR - surgical - not FDA approved, CE mark approved
EVAHEART - surgical - CE mark, trial pending
HVAD - surgical - CE mark, FDA approved for BTT (2012), DT trial pending
HeartAssist 5 - surgical - CE mark, FDA IDE, BTT trial pending
Heartmate III - surgical - CE mark pending, FDA IDE approved, BTT/DT trial pending
MVAD - surgical - CE mark pending, FDA IDE pending
SynCardia TAH - surgical - pulsatile pneumatic, CE mark approved, FDA humanitarian device exemption 2004

49
Q

What are the ACCF/AHA HF Stages?

A

Stage A - At risk but no structural heart disease
Stage B - Structural heart disease but no signs or symptoms of HF
Stage C - Structural heart disease but with past or current signs or symptoms of HF
Stage D - Refractory HF requiring specialized interventions

50
Q

What is the NYHA Classification?

A

I - no limitation in physical activity
II - mild limitation in physical activity - ordinary physical activity results in symptoms
III - marked limitation of physical activity - 1 flight of stairs
IV - symptoms at rest or unable to carry out any physical activity without symptoms of HF

51
Q

What is the INTERMACS Classification and what are the stages?

A

A classification of NYHA III-IV patients to stratify these patients in more detail. Developed in 2008.

1 - crash and burn - intervention needed within hours
2 - sliding on inotropes - intervention needed within days
3 - stable on inotropes but repeated failure to wean - dependent stability - intervention needed elective over a few weeks
4 - frequent flyer - elective over weeks to months as long as treatment of episodes restores stable baseline, including nutrition
5 - housebound - intervention needed variably, depending on nutrition, organ function and activity
6 - walking wounded - intervention needed variably, depending on nutrition, organ function and activity
7 - patient living comfortably with meaningful activity limited to mild exertion - transplant or MCS not currently indicated

52
Q

Which scores are used to predict peri-operative mortality?

A

3 risk scores:
MELD score
MELD-XI score for patients on warfarin
Heartmate II multivariable risk score (HMRS)

53
Q

Relative contraindications to MCS?

A

Irreversible major end-organ dysfunction, severe hemodynamic instability, profound coagulopathy, complex congenital anomalies, restrictive heart disease with decreased ventricular dimensions, active infection (wait 5 days after culture documented clearance from infection before surgery), chronic pre-operative dialysis

54
Q

What concurrent operations are indicated in LVAD implantation?

A

bioprosthetic AVR - moderate or greater AI
bioprosthetic TVR or repair with ring - moderate or greater TR
PFO or ASD closure

55
Q

Why can LVAD implantation cause RV failure?

A
  1. Sudden increase in cardiac output and venous return (increased preload)
  2. LVAD reduces pulmonary hypertension (afterload) but it can take time which does not help the RV
  3. Interdependence between the RV and LV can result in RV distortion and dysfunction due to LV unloading.
56
Q

What are the average flows of Heartmate II, III and HVAD?

A

10000, 5000 and 2500 respectively.

57
Q

What are the parameters of Centrimag?

A
Pump speed 3000-4000
Pump flows 4-5L
RAP/LAP 10-15mmHg
CVP 8-12mmHg
Target ACT 160-180s
58
Q

What is a PAPI? (Pulmonary artery pulsatility index)

A

Systolic pulmonary artery pressure - diastolic pulmonary artery pressure / right atrial pressure. A PAPI under 1.85 is used to predict RV dysfunction post LVAD

59
Q

What is the RV stroke work index used for and what is the formula?

A

It is used to determine need for potential RVAD during LVAD implant
RVSWI >6 - no need for RVAD
RVSWI 4-6 - consider NO and RVAD
RVSWI <4 - consider RVAD

Formula:
Mean PA - CVP x SWI x 13.6 = RVSWI

60
Q

<p><strong>REMATCH</strong> Trial - primary endpoint and result</p>

A

<p>Survival at <strong>1yr</strong></p>

<p><strong>50%</strong> - HeartMate XVE</p>

<p><strong>25%</strong> - Control</p>

<p></p>

<p>Survival at <strong>2yrs</strong></p>

<p><strong>20%</strong> - HeartMate XVE (Impacted by device failure/complications)</p>

<p><strong>10%</strong> - Control</p>

<p>(NEJM 2001)</p>

61
Q

<p>Trial demonstrating feasibility and safety of <strong>Continuous</strong> Flow vs. <strong>Pulsatile</strong> Flow devices</p>

A

<p>HeartMate II BTT/DTTrial (NEJM 2009/ATS 2006)</p>

<p>Compared HeartMate <strong>VE</strong> <strong>(continuous)</strong>vs. HeartMate <strong>XVE</strong> <strong>(pulsatile)</strong></p>

<p><strong>BTT</strong></p>

<p>Primary Endpoint: <strong>2-year</strong> Composite⇒ <strong>45%</strong> vs. <strong>10%</strong></p>

<ol>
<li><strong>Death</strong></li>
<li>Disabling <strong>Stroke</strong></li>
<li>Reop for <strong>Device Failure</strong><strong>​</strong></li>
</ol>

<p><strong>DT</strong></p>

<p>HeartMate VE improved</p>

<ol>
<li>Adverse Event Profile<strong> </strong>(device <strong>malfunction</strong>)</li>
<li>Hospital<strong>Readmission</strong></li>
<li><strong>Functional capacity</strong></li>
<li><strong>Survival</strong></li>
</ol>

62
Q

<p><strong>ENDURANCE</strong> Trial Primary Endpoint and Results</p>

A

<p>(NEJM 2017) <strong>RCT</strong></p>

<p><strong>HeartWare</strong> vs. <strong>HeartMate II</strong></p>

<p>Primary Endpoint: 2-year Composite⇒ <strong>55%</strong> vs. <strong>60% non-inferior</strong></p>

<ol>
<li><b>Death</b></li>
<li>Disabling<strong>Stroke</strong></li>
<li>Reop for<strong>Device Failure</strong></li>
</ol>

<p>HeartWare⇒ more device failure</p>

<p>HeartMate II⇒ more strokes</p>

63
Q

<p><strong>Momentum III</strong> Trial Primary Endpoint and Results</p>

A

<p>(NEJM 2016)<strong>RCT</strong></p>

<p>HeartMate<strong> III </strong>vs.<strong> II</strong></p>

<p>Primary Endpoint: 6-month Composite⇒<strong>85%</strong>vs.<strong>75%</strong></p>

<ol>
<li><strong>Death</strong></li>
<li>Disabling<strong>Stroke</strong></li>
<li>Reop for<strong>Device Failure</strong></li>
</ol>

<p>HeartMate III⇒ less pump failure</p>

<p></p>

64
Q
A
65
Q

<p><strong>Pulsatile</strong> vs. <strong>Continuous</strong> Flow Device - <strong>Adverse Event</strong> Profile</p>

A

<p>Table</p>

66
Q

<p>Temporary MCS Devices</p>

A

<p>IABP</p>

<p>ECMO</p>

<p>Impella (2.5/5.0/CP/RP)</p>

<p>CentriMag</p>

<p>TandemHeart (pVAD)</p>

67
Q

<p>Compare/Contrast the <strong>ACC/AHA</strong> vs. <strong>NYHA</strong> Classifications of <strong>CHF</strong></p>

A

<p>Table</p>

68
Q

<p>What does <strong>INTERMACS</strong> stand for?</p>

A

<p><strong>Inter</strong>-Agency Registry for <strong>M</strong>echanically<strong>A</strong>ssisted <strong>C</strong>irculatory<strong> S</strong>upport</p>

69
Q

<p><strong>INTERMACS</strong> Classification System</p>

<p></p>

A

<p><strong>1) “Crash and Burn” </strong>- persistent HoTN despite increasing inotropes; MSOF; increasing lactate, worsening acidosis</p>

<p><strong>2) “Sliding on Inotropes”</strong>- worsening renal function, nutritional delpetion, refractory volume overload</p>

<p><strong>3) "Dependant Stability"</strong>- stable BP, oragn function and nutritional status but unable to wean inotropes</p>

<p><strong>4) "Frequent Flyer"</strong>- recurrent episodes of volume overload and hospital readmissions</p>

<p><strong>5) "Housebound"</strong>- NYHA IV;fatigues with ADLs</p>

<p><strong>6) "Walking Wounded"</strong>- comfortable at rest but fatigues with exertion</p>

<p><strong>7) "Placeholder"</strong>- Advanced NYHA III</p>

70
Q

<p><strong>Contraindications</strong> to <strong>Longterm MCS</strong> Device Implantation</p>

A

<p><strong>Irreversible</strong> End Organ Dysfunction</p>

<p>Severe <strong>Hemodynamic</strong> Instability</p>

<p>Profound <strong>Coagulopathy</strong></p>

<p>Complex <strong>Congenital</strong> Abnormalities</p>

<p>Restrictive Cardiac Disease (<strong>small LV </strong>dimensions)</p>

<p>Questionable<strong>Neurological</strong>Status</p>

71
Q

<p>HeartMate II Multivariate Risk Score (<strong>HMRS</strong>)</p>

A

<p><span>Predicts <strong>90-day</strong> postoperative <strong>mortality</strong></span></p>

<p><span>Variables:</span></p>

<ol>
<li><span>Age</span></li>
<li><span>Albumin</span></li>
<li><span>Creatinine</span></li>
<li><span>INR</span></li>
<li><span>Implanting Center Volume</span></li>
</ol>

<p></p>

<p><span><strong>Low</strong> Risk < 1.5 ⇒5%</span></p>

<p><span><strong>Medium</strong> Risk 1.5-2.5 ⇒ 15%</span></p>

<p><span><strong>High</strong><strong> </strong>Risk > 2.5 ⇒30%</span></p>

72
Q

<p><strong>MELD</strong>vs.<strong>MELD-XI</strong>vs. <strong>MELD-Na</strong>Scores</p>

A

<p><strong>MELD </strong></p>

<ol>
	<li>Bilirubin</li>
	<li>Creatinine</li>
	<li>INR</li>
</ol>

<p></p>

<p><strong>MELD-XI</strong> (anticoagulation compatible)</p>

<ol>
<li>Bilirubin</li>
<li>Creatinine</li>
</ol>

<p></p>

<p><strong>MELD-Na</strong></p>

<ol>
	<li>Bilirubin</li>
	<li>Creatinine</li>
	<li>INR</li>
	<li>Sodium</li>
</ol>
73
Q

<p>Cardiac lesions that should be addressed at the time of longterm VAD implantation</p>

A

<p>Moderate to severe <strong>AI </strong></p>

<p><strong>PFO</strong>/ASD</p>

74
Q

<p>How do you deal with <strong>AI</strong> at the time of <strong>LVAD</strong> inplantation?</p>

A
<ol>
	<li><strong>Park Stich</strong></li>
	<li><strong>Bicuspidize</strong></li>
	<li><strong>Oversew</strong> the Valve</li>
	<li><strong>Bioprosthesis</strong></li>
</ol>
75
Q

<p>Causes of <strong>Acquired AI</strong> with LVAD</p>

A

<ol>
<li>Elevated <strong>Sheer Stress</strong></li>
<li>Elevated Transvalvular <strong>Gradient</strong></li>
<li>Decreased AoV <strong>Opening</strong></li>
<li>Abnormal AoV <strong>Biomechanics</strong></li>
</ol>

76
Q

<p><strong>Guidelines</strong> for when to address <strong>AI</strong>, <strong>PFO</strong>, <strong>MS</strong> and <strong>TR</strong> at the time of <strong>LVAD</strong> Impantation</p>

A

<p><strong>Class I</strong></p>

<p>Presence of <strong>PFO</strong>⇒ Close</p>

<p><strong>AI > mild</strong>⇒ Park Stitch, Oversew, BioAVR</p>

<p><strong>MS > mild</strong>⇒ Repair or BioMVR</p>

<p><strong>Class IIa</strong></p>

<p><strong>TR > mild</strong>⇒ Repair</p>

<p><strong>MR</strong> reasonable to repair if <strong>bridge to recovery</strong></p>

77
Q

<p><strong>Risk Factors</strong> for <strong>RHF</strong> after <strong>LVAD</strong> Implantation</p>

A

<ol>
<li>Preop Mechanical <strong>Ventilation</strong></li>
<li>Increased <strong>CVP</strong></li>
<li>Increased <strong>CVP/PCWP</strong></li>
<li>Decreased <strong>RV Stroke Work Index</strong></li>
<li><strong>RV Dysfunction</strong></li>
<li><strong>TR</strong></li>
<li>Elevated <strong>WBC</strong></li>
<li>Elevated <strong>BUN</strong></li>
</ol>

78
Q

<p><strong>Echo</strong>cardiographic <strong>Predictors</strong> of <strong>RHF</strong> after <strong>LVAD</strong></p>

A

<ol>
<li>Reduced <strong>free-wall strain</strong></li>
<li><strong>RV/LV diameter</strong> ratios</li>
<li><strong>TR</strong><b> </b>severity</li>
<li><strong>RVEF</strong></li>
</ol>

79
Q

<p>Which devices are currently <strong>FDA</strong> approved for...</p>

<p></p>

<p><strong>Bridge-to-Transplant</strong>?</p>

<p><strong>Destination Therapy</strong>?</p>

A

<p>Bridge-to-Transplant:</p>

<ol>
	<li><strong>HeartMate II</strong></li>
	<li><strong>HeartMate III</strong></li>
	<li><strong>Heartware (HVAD)</strong></li>
	<li><strong>SynCardia TAH</strong></li>
</ol>

<p></p>

<p>Destination Therapy</p>

<ol>
<li><strong>HeartMate II</strong></li>
</ol>

80
Q

<p>Factors Required to meet Indicationfor<strong> Destination Therapy</strong></p>

A

<ol>
<li>Not a <strong>Transplant Candidate</strong></li>
<li>Refractory <strong>HF</strong> despite <strong>OMT</strong>
<ol>
<li><strong>​NYHA III-IV</strong></li>
<li><strong>Frequent Flyer</strong></li>
<li><strong>Diruetic Dependant</strong></li>
<li><b>VO2< 14mL/kg/min</b></li>
</ol>
</li>
<li>Life Expectancy <strong>> 2-years</strong></li>
<li>No Irreversable <strong>End Organ Damage</strong></li>
<li>No Hx of <strong>Non-Compliance</strong> or <strong>Psychosocial</strong> Limitations</li>
</ol>

81
Q

<p><strong>Durable </strong>(Longterm)MCSDevices</p>

A
<ol>
	<li>HeartMate II</li>
	<li>HeartMate III</li>
	<li>HeartWare (HVAD)</li>
	<li>SynCardia TAH (pulsitile)</li>
</ol>
82
Q

<p><strong>TEE</strong>Parameters used to adjust <strong>LVAD</strong> speed intraoperatively</p>

A

<ol>
<li><strong>Chamber Size</strong></li>
<li><strong>Interventricular Septum</strong> Position</li>
<li>Degree of <strong>MR</strong></li>
<li><strong>RV</strong> Function</li>
<li><strong>Aortic Valve</strong> Opening</li>
</ol>

83
Q

<p><strong>Direct</strong> and <strong>Calculated</strong> VAD Parameters</p>

A

<p>Direct</p>

<ol>
<li><strong>Speed</strong> (rpm)</li>
<li><strong>Power</strong> expenditure (watts)</li>
</ol>

<p>Calculated</p>

<ol>
<li><strong>Flow</strong>(L/min)</li>
<li><strong>Pulsitility Index</strong>(HeartMate II only)</li>
</ol>

84
Q

<p>Causes of <strong>Increased Velocity</strong> at the <strong>Inflow</strong> <strong>Cannula</strong></p>

A

<ol>
<li><strong>Suction Event</strong> (hypovolemia or inadequate preload)</li>
<li>Poor <strong>Cannula Placement</strong> (spetum or trabeculae)</li>
<li><strong>Pump Thrombosis</strong></li>
</ol>

85
Q

<p>Standardized Markers of <strong>RV Dysfunction</strong> following <strong>LVAD</strong></p>

A

<ol>
<li>Inability to wean from <strong>CPB</strong></li>
<li><strong>MAP</strong> < 55mmHg</li>
<li><strong>CVP</strong> > 16mmHg</li>
<li><strong>SvO2</strong>< 55%</li>
<li>LV <strong>Flow</strong> Rate Index < 2L/min/m2</li>
<li>Significant <strong>Inotrope</strong> Dependence</li>
</ol>

86
Q

<p><strong>Management</strong> of <strong>RHF</strong> after <strong>LVAD</strong> Implantation</p>

A

<ol>
<li><strong>Inotropes</strong>(Milrinone, Dobutamine, Isoproterenol, Epinephrine)</li>
<li><strong>Diuresis</strong></li>
<li><strong>Sinus Rhythm</strong></li>
<li>Redeuce PVR (<strong>Inhaled NO</strong>)</li>
<li><strong>RVAD</strong></li>
</ol>

87
Q

<p><strong>ISHLT</strong> Guidelines for <strong>Anticoagulation</strong> with <strong>Durable VAD</strong> Therapy</p>

A

<p>POD #1</p>

<ol>
<li>IV <strong>Heparin</strong></li>
</ol>

<p>POD #3</p>

<ol>
<li><strong>Aspirin</strong></li>
<li><strong>Warfarin</strong> (INR 2-3)</li>
</ol>

88
Q

<p><strong>Surivival</strong> following <strong>LVAD</strong> Implantation</p>

A

<p><strong>30-day </strong>Survival - <strong>90%</strong></p>

<p><strong>1-year</strong>Survival-<strong>85%</strong></p>

<p></p>

<p>(HeartWare ADVANCE Trial and INTERMACS Registry)</p>

89
Q

<p><strong>Risk Factors</strong> Predicting Poor <strong>Survival</strong> After <strong>LVAD</strong> Implantation</p>

A

<ol>
<li><strong>INTERMACS 1 or 2</strong></li>
<li><strong>Renal</strong> Dysfunction</li>
<li><strong>Age > 70</strong></li>
<li><strong>RV</strong> Dysfunction</li>
<li>Need for<strong>BiVAD</strong></li>
<li>Increased <strong>Surgical Complexity</strong></li>
</ol>

90
Q

<p><strong>LVAD</strong> vs. <strong>Rx</strong> pre-Transplant <strong>Mortality</strong> and <strong>QOL</strong></p>

A

<p>30-day, 1 and 2-year Survival is Statistically equivalent</p>

<p><strong>30-day</strong> Survival - <strong>95%</strong></p>

<p><strong>1-year</strong> Survival - <strong>80%</strong></p>

<p><strong>2-year</strong> Survival - <strong>70%</strong></p>

<p></p>

<p><strong>QOL improves</strong> with <strong>LVAD</strong> while awaiting transplant</p>

91
Q

<p><strong>Adverse Event</strong> Rates of <strong>LVAD</strong> Therapy</p>

A

<ol>
<li><strong>Bleeding</strong>(Reop for bleeding 30% with >50% requiring blood products; GI bleedingrates 20-30% )</li>
<li><strong>Device Malfunction</strong></li>
<li><strong>Renal Failure</strong>(15-30%)</li>
<li><strong>Infection</strong>(10-20% driveline infections by 1-year)</li>
<li><strong>Stroke </strong>(10/20% at 1-/2-years - ischemic = hemorrhagic)</li>
<li><strong>Death</strong></li>
</ol>

<p></p>

<p><strong>30</strong>-days - <strong>40%</strong></p>

<p><strong>1</strong>-year - <strong>70%</strong></p>

<p><strong>2</strong>-years - <strong>80%</strong></p>

<p><strong>3</strong>-years - <strong>85%</strong></p>

92
Q

<p>Proposed <strong>causes</strong> of increased <strong>GI bleeding</strong> with <strong>CF</strong> <strong>VADs</strong></p>

A

<ol>
<li>Acquired <strong>von Willebrand</strong> Syndrome</li>
<li><strong>AVM</strong> Formation (<strong>Non-Pulsitile</strong> flow)</li>
<li><strong>Anticoagulation</strong></li>
</ol>

<p></p>

93
Q

<p>Suspected vs. Confirmed <strong>Pump Thrombosis</strong></p>

A

<p>Suspected</p>

<ol>
<li><strong>Hemolysis</strong>(Serum-free hemoglobin >40mg/dL or LDH >600IU/L)</li>
<li>Unexplained <strong>CHF</strong> Symptoms</li>
<li>Abnormal Pump <strong>Parameters</strong></li>
</ol>

<p>Confirmed</p>

<ol>
<li><strong>Direct</strong> Inspection</li>
<li><strong>Radiographic</strong> Imaging</li>
</ol>

94
Q

<p><strong>Histologic</strong> and <strong>Hormonal</strong> Features of <strong>Reverse Remodeling</strong> for BTR</p>

A

<p><strong>Histologic</strong></p>

<ol>
<li>Decreased <strong>Collagen/Fibrosis</strong></li>
<li>Decreased <strong>MMP</strong> Activity</li>
<li>Decreased Myocardial <strong>Apoptosis</strong></li>
<li>Decreased Myocardial <strong>Hypertrophy/Myofibrillar Disarray</strong></li>
<li>Increased <strong>SR Calcium</strong></li>
</ol>

<p><strong>​</strong></p>

<p><strong>Hormonal</strong></p>

<ol>
<li>Decreased <strong>Sympathetic Tone</strong></li>
<li>Decreased <strong>BNP</strong></li>
<li>Decreased <strong>RAAS</strong></li>
<li>Decreased <strong>ET-1</strong></li>
<li>Decreased Infalmmatory <strong>Cytokines</strong> (IL-6, IL-8, TNFa)</li>
</ol>